Antegene to Pay $162 Million for China Rights to Four Karyopharm Assets

Shanghai's Antengene has licensed China rights to four novel oral drug candidates developed by Karyopharm of Boston in an $162 million agreement.  Karyopharm's candidates, which are based on inhibiting nuclear transport and related targets, are intended mainly for oncology indications. Antegene will pay $12 million upfront and up to $150 million in milestones, plus royalties. It will be responsible for all costs, but will have rights to develop, manufacture and commercialize the four compounds in greater China. More details....

Stock Symbol: (NSDQ: KPTI)

Share this with colleagues:

Original Article: Antegene to Pay $162 Million for China Rights to Four Karyopharm Assets

More From BioPortfolio on "Antegene to Pay $162 Million for China Rights to Four Karyopharm Assets"